Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 4, 2013, Pages 437-444

  Su, Zhi Jun ^a   Yu, Xue Ping ^a   Guo, Ru Yi ^a   Ming, De Song ^a   Huang, Lv Ye ^a   Su, Mi Long ^a   Deng, Yong ^a   Lin, Zhen Zhong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B; IL 10; IL 17; TGF 1; Th17 cells; Treg cells

Indexed keywords

ALANINE AMINOTRANSFERASE; CD3 ANTIBODY; CD8 ANTIGEN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 7 RECEPTOR; NUCLEOSIDE ANALOG; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD25+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; TH17 CELL;

ALANINE AMINOTRANSFERASE; ALT; ASPARTATE AMINOTRANSFERASE; AST; CHB; CHB-LM; CHB-S; CHRONIC HEPATITIS B; DBIL; DC; DENDRITIC CELLS; DIRECT BILIRUBIN; ENTECAVIR; ETV; G-CSF; GRANULOCYTE COLONY-STIMULATING FACTOR; HAV; HBEAG; HBSAG; HBV; HC; HCV; HDV; HEALTHY CONTROLS; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B E ANTIGEN; HEPATITIS B SURFACE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS D VIRUS; ICAM-1; IL-10; IL-17; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-17; ION; IONOMYCIN; LOW TO MODERATE CHRONIC HEPATITIS B; MON; MONENSIN; NATURAL KILLER; NF-KAPPA B; NK; NUCLEAR FACTOR KAPPA B; PBMCS; PD-1; PERIPHERAL BLOOD MONONUCLEAR CELLS; PHORBOL 12-MYRISTATE-13-ACETATE; PMA; PROCEDURAL DEATH FACTOR-1; SEVERE CHRONIC HEPATITIS B; T; T HELPER 17; TBIL; TGF-Β1; TH17; TH17 CELLS; TOTAL BILIRUBIN; TRANSFORMING GROWTH FACTOR-Β1; TREG; TREG CELLS;

ADULT; ANTIGENS, CD; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CYTOKINES; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84880758206     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.04.026     Document Type: Article

References (32)

1. Ariyasu T., Tanaka T., Fujioka N., Yanai Y., Yamamoto S., Yamauchi H., et al. Effects of interferon-alpha subtypes on the TH1/TH2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders. In Vitro Cell Dev Biol Anim 2005, 41(1-2):50-56.
2. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238.
3. Choe W.H., Hong S.P., Kim B.K., Ko S.Y., Jung Y.K., Kim J.H., et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 2009, 14(7):985-993.
4. de Franchis R., Hadengue A., Lau G., Lavanchy D., Lok A., McIntyre N., et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003, 39(Suppl 1):S3-S25.
5. Ge J., Wang K., Meng Q.H., Qi Z.X., Meng F.L., Fan Y.C. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol 2010, 30(1):60-67.
6. Hanidziar D., Koulmanda M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. Curr Opin Organ Transplant 2010, 15(4):411-415.
7. Harrington L.E., Mangan P.R., Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006, 18(3):349-356.
8. Hsu Y.S., Chien R.N., Yeh C.T., Sheen I.S., Chiou H.Y., Chu C.M., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35(6):1522-1527.
9. Hu X., Ma S., Huang X., Jiang X., Zhu X., Gao H., et al. Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease. J Viral Hepat 2011, 18(7):458-467.
10. Huang D., Zuo Y., Zou Q., Wang Y., Gao S., Wang X., et al. Reinforced nanohydroxyapatite/polyamide66 scaffolds by chitosan coating for bone tissue engineering. J Biomed Mater Res B Appl Biomater 2011.
11. Imamura T., Yokosuka O., Kurihara T., Kanda T., Fukai K., Imazeki F., et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut. 2003, 52(11):1630-1637.
12. Karino Y., Toyota J., Kumada H., Katano Y., Izumi N., Kobashi H., et al. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 2010, 4(1):414-422.
13. Lao L., Wang Y., Zhu Y., Zhang Y., Gao C. Poly(lactide-co-glycolide)/hydroxyapatite nanofibrous scaffolds fabricated by electrospinning for bone tissue engineering. J Mater Sci Mater Med 2011, 22(8):1873-1884.
14. Lee W.D., Hurtig M.B., Kandel R.A., Stanford W.L. Membrane culture of bone marrow stromal cells yields better tissue than pellet culture for engineering cartilage-bone substitute biphasic constructs in a two-step process. Tissue Eng Part C Methods 2011, 17(9):939-948.
15. Lina C., Conghua W., Nan L., Ping Z. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 2011, 31(4):596-605.
16. Maruyama T., Kono K., Mizukami Y., Kawaguchi Y., Mimura K., Watanabe M., et al. Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 2010, 101(9):1947-1954.
17. Niu Y., Liu H., Yin D., Yi R., Chen T., Xue H., et al. The balance between intrahepatic IL-17(+) T cells and Foxp3(+) regulatory T cells plays an important role in HBV-related end-stage liver disease. BMC Immunol 2011, 12:47.
18. Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis 2007, 66(Suppl 3):iii87-iii90.
19. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6(11):1133-1141.
20. Peng G., Li S., Wu W., Sun Z., Chen Y., Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 2008, 123(1):57-65.
21. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203(7):1693-1700.
22. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24(2):179-189.
23. Weaver C.T., Hatton R.D. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009, 9(12):883-889.
24. Wu W., Li J., Chen F., Zhu H., Peng G., Chen Z. Circulating Th17 cells frequency is associated with the disease progression in HBV infected patients. J Gastroenterol Hepatol 2010, 25(4):750-757.
25. Xin L., Li Y., Soong L. Role of interleukin-1beta in activating the CD11c(high) CD45RB- dendritic cell subset and priming Leishmania amazonensis-specific CD4+ T cells in vitro and in vivo. Infect Immun 2007, 75(10):5018-5026.
26. Xu D., Fu J., Jin L., Zhang H., Zhou C., Zou Z., et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177(1):739-747.
27. Xue-Song L., Cheng-Zhong L., Ying Z., Mo-Bin W. Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection. BMC Gastroenterol 2012, 12:43.
28. Yang G., Liu A., Xie Q., Guo T.B., Wan B., Zhou B., et al. Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 2007, 19(2):133-140.
29. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116(5):1310-1316.
30. Yokosuka O., Takaguchi K., Fujioka S., Shindo M., Chayama K., Kobashi H., et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 2010, 52(6):791-799.
31. Zhang J.Y., Song C.H., Shi F., Zhang Z., Fu J.L., Wang F.S. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 2010, 5(11):e13869.
32. Zhang J.Y., Zhang Z., Lin F., Zou Z.S., Xu R.N., Jin L., et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010, 51(1):81-91.